We are live on ! Find out more
LGM

Logos Global Management Portfolio holdings

AUM $2B
1-Year Est. Return 444.09%
This Fund
S&P 500
This Quarter Est. Return
+93.02%
1 Year Est. Return
+444.09%
3 Year Est. Return
+1,593.63%
5 Year Est. Return
+2,146.66%
10 Year Est. Return
–
AUM
$406M
AUM Growth
–
Cap. Flow
+$328M
Cap. Flow %
80.95%
Top 10 Hldgs %
56.89%
Holding
40
New
40
Increased
–
Reduced
–
Closed
–

Top Buys

Rank Stock Value
1
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$24.5M
2
SAGE
Sage Therapeutics
SAGE
+$23.4M
3
SRPT icon
Sarepta Therapeutics
SRPT
+$22.8M
4
ASND icon
Ascendis Pharma A/S
ASND
+$20M
5
AMRN
Amarin Corp
AMRN
+$18.3M

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 81.96%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ISEE
26
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$4.49M 1.11%
+523,462
New +$1.87M
IGMS
27
DELISTED
IGM Biosciences
IGMS
$4.37M 1.08%
+114,411
New +$2.87M
ASMB icon
28
Assembly Biosciences
ASMB
$516M
$3.85M 0.95%
+15,667
New +$2.89M
BLU
29
DELISTED
BELLUS Health Inc.
BLU
$3.23M 0.8%
+424,618
New +$2.9M
KRTX
30
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
$2.99M 0.74%
+39,647
New +$1.74M
APTO
31
DELISTED
Aptose Biosciences, Inc.
APTO
$2.97M 0.73%
+1,164
New +$1.52M
LITS
32
Lite Strategy Inc
LITS
$33.2M
$2.84M 0.7%
+57,276
New +$2.13M
MDGL icon
33
Madrigal Pharmaceuticals
MDGL
$12.8B
$2.48M 0.61%
+27,279
New +$2.65M
SVRA icon
34
Savara
SVRA
$1.12B
$2.48M 0.61%
+613,999
New +$739K
ETNB
35
DELISTED
89bio
ETNB
$2.28M 0.56%
+86,591
New +$2.41M
FULC icon
36
Fulcrum Therapeutics
FULC
$247M
$2.06M 0.51%
+123,635
New +$1.18M
NERV icon
37
Minerva Neurosciences
NERV
$191M
$1.62M 0.4%
+28,479
New +$1.26M
ARDX icon
38
Ardelyx
ARDX
$1.27B
$1.59M 0.39%
+212,449
New +$1.29M
NGNE icon
39
Neurogene
NGNE
$679M
$499K 0.12%
+2,026
New +$202K
KZR
40
DELISTED
Kezar Life Sciences
KZR
$493K 0.12%
+12,293
New +$378K
1
2

Similar funds

MYAM
Meiji Yasuda Asset Management Tokyo, Japan $2B AUM 22.52% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.66% 1-Year Est. Return
LBC
Lowe Brockenbrough & Co Richmond, Virginia $2.01B AUM 22.05% 1-Year Est. Return
C
Consulta London, United Kingdom $2.01B AUM 16.82% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BGM
Burkehill Global Management New York $2.02B AUM 85.32% 1-Year Est. Return
SC
Syon Capital San Francisco, California $1.99B AUM 22.67% 1-Year Est. Return
AF
Alerus Financial Grand Forks, North Dakota $2.02B AUM 26.03% 1-Year Est. Return

Logos Global Management's Q4 2019 Portfolio in Review

Q4 2019 is the first quarter with a 13F filing on record for Logos Global Management, which disclosed 40 positions worth $406M. Its ten largest holdings account for 57% of the portfolio.

Its largest position is Mirati Therapeutics, Inc. Common Stock: 253,660 shares worth $32.7M.

By sector, the portfolio is most concentrated in Healthcare at 82% of assets.

  • Logos Global Management's largest Q4 2019 buy was Mirati Therapeutics, Inc. Common Stock: 253,660 shares worth $32.7M.
  • Logos Global Management's ten largest holdings make up 57% of its $406M portfolio in Q4 2019.
  • Logos Global Management disclosed 40 positions in Q4 2019, its first 13F filing on record.

Based on Logos Global Management's 13F filing for Q4 2019, filed 14 Feb 2020.